CNR2 and central nervous system cancer: Interestingly, local administration of the selective CB2 agonist—JWH133—or silencing CB2R expression induced a considerable regression of glioma by inducing glioma cell death (12, 38) and depressing the production of vascular endothelial growth factor (VEGF) in glioma cells (13).